Barclays PLC Sells 34,379 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Barclays PLC decreased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 20.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 130,826 shares of the medical research company’s stock after selling 34,379 shares during the quarter. Barclays PLC’s holdings in Charles River Laboratories International were worth $25,769,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of CRL. Oregon Public Employees Retirement Fund boosted its holdings in shares of Charles River Laboratories International by 1.0% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company’s stock valued at $914,000 after purchasing an additional 45 shares during the last quarter. Empirical Finance LLC boosted its stake in Charles River Laboratories International by 4.2% during the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock valued at $258,000 after buying an additional 53 shares during the last quarter. American Trust grew its holdings in Charles River Laboratories International by 5.9% during the 2nd quarter. American Trust now owns 976 shares of the medical research company’s stock valued at $202,000 after buying an additional 54 shares in the last quarter. Tortoise Investment Management LLC increased its stake in Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after acquiring an additional 57 shares during the last quarter. Finally, OLD National Bancorp IN raised its holdings in shares of Charles River Laboratories International by 3.1% during the 3rd quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock worth $392,000 after acquiring an additional 59 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on CRL shares. Evercore ISI boosted their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a report on Monday, November 18th. UBS Group increased their price target on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Citigroup downgraded Charles River Laboratories International from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. Finally, Bank of America dropped their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $214.00.

Insiders Place Their Bets

In other news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $190.45 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The company has a market capitalization of $9.74 billion, a PE ratio of 23.84, a P/E/G ratio of 5.00 and a beta of 1.38. The company has a 50 day moving average price of $194.35 and a 200-day moving average price of $203.10. Charles River Laboratories International, Inc. has a fifty-two week low of $176.48 and a fifty-two week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same period in the previous year, the company posted $2.72 EPS. Charles River Laboratories International’s revenue was down 1.6% on a year-over-year basis. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).